Search

BackgroundDuring the COVID-19 pandemic, the use of telemedicine as a way to reduce COVID-19 infections was noted and consequently deregulated. However, the degree of telemedicine regulation varies from country to country, which may alter the widespread use of telemedicine. This study aimed to clarify the telepsychiatry regulations for each collaborating country/region before and during the COVID-19 pandemic.MethodsWe used snowball sampling within a global network of international telepsychiatry experts. Thirty collaborators from 17 different countries/regions responded to a questionnaire on barriers to the use and implementation of telepsychiatric care, including policy factors such as regulations and reimbursement at the end of 2019 and as of May 2020.ResultsThirteen of 17 regions reported a relaxation of regulations due to the pandemic; consequently, all regions surveyed stated that telepsychiatry was now possible within their public healthcare systems. In some regions, restrictions on prescription medications allowed via telepsychiatry were eased, but in 11 of the 17 regions, there were still restrictions on prescribing medications via telepsychiatry. Lower insurance reimbursement amounts for telepsychiatry consultations v. in-person consultations were reevaluated in four regions, and consequently, in 15 regions telepsychiatry services were reimbursed at the same rate (or higher) than in-person consultations during the COVID-19 pandemic.ConclusionsOur results confirm that, due to COVID-19, the majority of countries surveyed are altering telemedicine regulations that had previously restricted the spread of telemedicine. These findings provide information that could guide future policy and regulatory decisions, which facilitate greater scale and spread of telepsychiatry globally.

BackgroundDuring the COVID-19 pandemic, the use of telemedicine as a way to reduce COVID-19 infections was noted and consequently deregulated. However, the degree of telemedicine regulation varies from country to country, which may alter the widespread use of telemedicine. This study aimed to clarify the telepsychiatry regulations for each collaborating country/region before and during the COVID-19 pandemic.MethodsWe used snowball sampling within a global network of international telepsychiatry experts. Thirty collaborators from 17 different countries/regions responded to a questionnaire on barriers to the use and implementation of telepsychiatric care, including policy factors such as regulations and reimbursement at the end of 2019 and as of May 2020.ResultsThirteen of 17 regions reported a relaxation of regulations due to the pandemic; consequently, all regions surveyed stated that telepsychiatry was now possible within their public healthcare systems. In some regions, restrictions on prescription medications allowed via telepsychiatry were eased, but in 11 of the 17 regions, there were still restrictions on prescribing medications via telepsychiatry. Lower insurance reimbursement amounts for telepsychiatry consultations v. in-person consultations were reevaluated in four regions, and consequently, in 15 regions telepsychiatry services were reimbursed at the same rate (or higher) than in-person consultations during the COVID-19 pandemic.ConclusionsOur results confirm that, due to COVID-19, the majority of countries surveyed are altering telemedicine regulations that had previously restricted the spread of telemedicine. These findings provide information that could guide future policy and regulatory decisions, which facilitate greater scale and spread of telepsychiatry globally.

Over 6.5 million women in the United States suffer from female stress urinary incontinence (SUI). Only ~200,000 women choose surgery. There may be a role for a non-surgical, minimally invasive procedure that provides thermal shrinkage/remodeling of submucosal collagen in the endopelvic fascia. This study describes design, characterization, and preliminary testing of a novel probe with integrated contact cooling for potential use in transvaginal laser treatment of SUI. Laser energy at a deeply penetrating, near-infrared wavelength of 1075 nm was delivered through a 600-Lm-core fiber optic patchcord into a 90o side-firing probe head (19 x 22 mm) with integrated flow cell and sapphire window cooled to - 2[degrees]C by circulating an alcohol-based solution. An inflatable balloon attached to the probe insured contact with vaginal wall. A force sensor and thermocouples monitored pressure and temperature. Thermal lesions were created in vaginal tissue of three cadavers (power = 4.6-6.4 W; spot diameter = 5.2 mm; time = 30 s). Thermal lesion areas measured 3.1-4.6 [mm.sup.2], while preserving the vaginal wall to a depth of 0.8-1.1 mm. Consistent tissue contact and cooling was maintained using the force sensors. Preliminary cadaver studies demonstrated subsurface treatment of endopelvic fascia with partial preservation of the vaginal wall. Future studies will optimize parameters for thermal remodeling with further tissue surface preservation. Keywords: cadaver, laser, minimally invasive, nonsurgical, remodeling, stress urinary incontinence, thermal, INTRODUCTION Over 6.5 million women in the U.S. suffer from stress urinary incontinence (SUI), while only ~200,000 women choose surgery [1,2]. The need for general anesthesia, long recovery time, incisions, [...]